T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2017

  • ID: 4426907
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biotest AG
  • Bristol-Myers Squibb Co
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • Sanofi
  • MORE
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2017

Summary

According to the recently published report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, H2 2017'; T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 22 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu.

The report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1, 8 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 6 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Metabolic Disorders and Undisclosed which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Encephalitis, Graft Versus Host Disease (GVHD), Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes), Unspecified and West Nile Virus Infections.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biotest AG
  • Bristol-Myers Squibb Co
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • Sanofi
  • MORE
Introduction

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development

Biotest AG

Bristol-Myers Squibb Co

CEL-SCI Corp

Fountain Biopharma Inc

Immupharma Plc

Sanofi

TaiMed Biologics Inc

United Biomedical Inc

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles

Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

forigerimod acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-48U1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAX-16H5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate CD4 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target CD4 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMB-360 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMB-365 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tregalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-421 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones

Featured News & Press Releases

Nov 02, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study2017

Oct 04, 2017: Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017

Sep 26, 2017: ImmuPharma initiates preparation of Lupuzors regulatory submissions

Sep 21, 2017: ImmuPharma Announces Update on Lupuzor Pivotal Phase III Study

Sep 20, 2017: Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS

Sep 18, 2017: Ibalizumab Long-Term Safety and Efficacy Data to be Presented at IDWeek 2017 in San Diego

Aug 03, 2017: The U.S. FDA Completed Pre-License Inspection of WuXi Biologics cGMP Manufacturing Facilities for Production of TMB-355 (ibalizumab)

Jul 24, 2017: Theratechnologies Announces New Findings from Investigational Antiretroviral Ibalizumab

Jun 30, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study - Annual General Meeting and Investor Presentation

Jun 30, 2017: FDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

May 17, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study

May 03, 2017: Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Apr 25, 2017: United BioPharma selects GE Healthcare’s FlexFactory to build late-stage clinical and commercial production capacity for biopharmaceuticals

Feb 15, 2017: Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Feb 14, 2017: Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Biotest AG, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by CEL-SCI Corp, H2 2017

Pipeline by Fountain Biopharma Inc, H2 2017

Pipeline by Immupharma Plc, H2 2017

Pipeline by Sanofi, H2 2017

Pipeline by TaiMed Biologics Inc, H2 2017

Pipeline by United Biomedical Inc, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biotest AG
  • Bristol-Myers Squibb Co
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • Sanofi
  • TaiMed Biologics Inc
  • United Biomedical Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll